| __timestamp | AstraZeneca PLC | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 94231000 |
| Thursday, January 1, 2015 | 5997000000 | 146394000 |
| Friday, January 1, 2016 | 5890000000 | 188272000 |
| Sunday, January 1, 2017 | 5757000000 | 166707000 |
| Monday, January 1, 2018 | 5932000000 | 401843000 |
| Tuesday, January 1, 2019 | 5958000000 | 560909000 |
| Wednesday, January 1, 2020 | 5991000000 | 722343000 |
| Friday, January 1, 2021 | 9736000000 | 771182000 |
| Saturday, January 1, 2022 | 9762000000 | 877090000 |
| Sunday, January 1, 2023 | 10935000000 | 877387000 |
| Monday, January 1, 2024 | 13583000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC and Sarepta Therapeutics, Inc. have shown contrasting approaches in their R&D investments. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, peaking at over $10 billion in 2023. This reflects their aggressive strategy to maintain a leading edge in drug development. In contrast, Sarepta Therapeutics, a smaller player, increased its R&D spending by approximately 830% during the same period, reaching close to $880 million in 2023. This remarkable growth underscores Sarepta's dedication to expanding its niche in genetic medicine. While AstraZeneca's vast resources allow for broad-spectrum research, Sarepta's focused investments highlight its strategic commitment to specialized therapies. This spending showdown offers a fascinating glimpse into the diverse strategies driving pharmaceutical innovation today.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
argenx SE or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
R&D Insights: How Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation